EP3146959A1 - Composition and use in treatment of a detached retina - Google Patents
Composition and use in treatment of a detached retina Download PDFInfo
- Publication number
- EP3146959A1 EP3146959A1 EP16152302.2A EP16152302A EP3146959A1 EP 3146959 A1 EP3146959 A1 EP 3146959A1 EP 16152302 A EP16152302 A EP 16152302A EP 3146959 A1 EP3146959 A1 EP 3146959A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- oil
- composition
- mpas
- viscosity
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 206010038848 Retinal detachment Diseases 0.000 title claims description 16
- 238000011282 treatment Methods 0.000 title claims description 12
- 239000003921 oil Substances 0.000 claims abstract description 69
- 229920002545 silicone oil Polymers 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 15
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- -1 polydimethylsiloxanes Polymers 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 description 11
- 230000000996 additive effect Effects 0.000 description 11
- 239000012530 fluid Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000004264 retinal detachment Effects 0.000 description 9
- 239000007789 gas Substances 0.000 description 7
- 210000001525 retina Anatomy 0.000 description 7
- 208000002367 Retinal Perforations Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 4
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 3
- 101100477605 Arabidopsis thaliana SRT2 gene Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 206010038897 Retinal tear Diseases 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229960004065 perflutren Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960000909 sulfur hexafluoride Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000033796 Pseudophakia Diseases 0.000 description 1
- 206010048955 Retinal toxicity Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 231100000385 retinal toxicity Toxicity 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Definitions
- the present invention relates to an oil composition and its use in the treatment of retinal detachment.
- Retinal detachment is the separation of the neurosensory retina from its underlying pigment epithelium. Untreated, retinal detachment can result in permanent vision loss or blindness. Retinal detachment is caused by traction of the vitreous upon the retina. The traction can be 'dynamic', caused by eye movements and thus relative movement of the vitreous and the retina; or 'static', due to contraction of membranes on the surface of the retina. Retinal detachments are associated with myopia, pseudophakia, trauma and diabetes; it is often the common pathway leading to blindness in a host of ophthalmic eye diseases.
- retinal detachment is associated with retinal breaks (also referred to as perforations, holes or tears), fluid gains access from the vitreous cavity to the subretinal space.
- This form of retinal detachment is referred to as 'Rhegmatogenous'.
- One effective method of closing retinal breaks involves the application of explants outside the eye in order to buckle the sclera (such as described in US 6,547,714 ).
- Internal tamponades are agents injected into the vitreous cavity to occlude retinal breaks. They are fluids that are immiscible with water and form an interface with it.
- the fluid can be gaseous such as air, sulphur hexafluoride (SF 6 ) or perfluoropropane (C 3 F 8 ). These gases can be used undiluted in small volumes or mixed with air and totally fill the vitreous cavity.
- the liquids include perfluorocarbon liquids, semifluorinated alkanes or alkenes and silicone oil. Of these, only silicone oil can be tolerated in the eye for more than a few weeks. Prolonged use of any of the other liquids will give rise to retinal toxicity as demonstrated by inflammatory reaction or by histological changes.
- Retinal detachments can also be treated by means of pneumatic retinopexy, whereby a gas bubble is injected into the vitreous space so as to help push the retinal tear back against the wall of the eye.
- This method can also be used in conjunction with the laser and cryo-surgical techniques if required.
- the gases preferred for such operations are commonly either perfluoropropane (C 3 F 8 ) or sulphur hexafluoride (SF 6 ), which when mixed with sterile air have the properties of remaining in the eye for extended periods of time.
- RU2235527 discloses a number of other gases that may also be used in conjunction with this technique. Eventually, the gas is replaced by the eyes own natural fluid, although there have been recent concerns over the toxicology of compositions that are fluorine based.
- Another method of treatment involves a vitrectomy whereby all or part of the vitreous gel is removed from the eye and replaced with a tamponade agent, such as a perfluorocarbon liquid, silicone oil or a gas (using a similar gaseous composition as described above) and the eye is allowed to fill with the body's own fluid over time.
- a tamponade agent such as a perfluorocarbon liquid, silicone oil or a gas (using a similar gaseous composition as described above) and the eye is allowed to fill with the body's own fluid over time.
- a small incision is made in the wall of the eye and the vitreous gel is removed by means of a small cutting device.
- a saline solution is used to maintain the pressure by a continuous infusion. This solution is then exchanged with an air infusion following which an air and gas mixture is injected.
- perfluorocarbon liquids, semifluorinated alkanes or alkenes and more commonly silicone oil is injected as a tamponade agent.
- the tamponade agent is the immiscible fluid that occludes retinal breaks because of its interfacial tension and its buoyancy. The tamponade material is therefore intended to close the retinal tear and reoppose the retina on the underlying choroids.
- Emulsification causes a number of specific problems; firstly the emulsified droplets can stimulate adverse biological responses including inflammatory reactions. Secondly, blocking of fluid to the eye decreases aqueous outflow and can cause raised intraocular pressure and glaucoma. Thirdly, reduction of vision by opacification of the fluid within the eye, and lastly the emulsion cannot tamponade the retina.
- compositions for use in the treatment of a detached retina which contain only a small amount of a high molecular weight, viscous, additive, in a less viscous oil.
- the present invention provides a composition comprising at least a first oil and a second oil, wherein the oils are miscible, wherein the first oil has a molecular weight of 100,000 or greater, and is present in an amount of at least 20% by weight, and wherein the second oil has a viscosity of 2,000 mPas or less.
- the present invention provides the above-mentioned composition for use in therapy.
- the present invention provides the above-mentioned composition for use in the treatment of a detached retina.
- the present invention provides a method of treatment of a detached retina in a patient in need thereof comprising the administration of an effective amount of the above-mentioned composition.
- the present invention is directed to a composition which has a relatively large amount (compared to the prior art) of high molecular weight component diluted by a low viscosity component.
- the composition is very effective and exhibits a low injection time despite the fact that 20% or more by weight of a high molecular weight additive is used.
- the skilled person would expect the shear viscosity of the composition to be high because of the presence of the significant proportion of high molecular weight additive, and therefore would not expect the composition to be convenient to use.
- the composition is very effective and is injectable in a short period of time.
- the molecular weight of the first oil may be 200,000 or greater, or 300,000 or greater.
- the molecular weight of the first oil may be up to 1,000,000, or up to 600,000, or up to 500,000, or up to 450,000. Possible molecular weight ranges therefore include 100,000 - 1,000,000, 200,000 - 600,000, 200,000 - 500,000, and 300,000 - 450,000, for example.
- the first oil in terms of its molecular weight, it may be defined in terms of its viscosity.
- the viscosity may be 10,000 mPas or greater, optionally 50,000 mPas or greater, optionally 100,000 mPas or greater, optionally 300,000 mPas or greater, optionally 500,000 mPas or greater, optionally 800,000 mPas or greater, optionally 1,000,000 mPas or greater.
- the viscosity may be up to 25,000,000 mPas, optionally up to 10,000,000 mPas, optionally up to 5,000,000 mPas, optionally up to 1,000,000 mPas. Suitable ranges include, for example, 10,000 mPas to 25,000,000 mPas, 50,000 mPas to 10,000,000 mPas, or 100,000 mPas to 1,000,000 mPas.
- the viscosity of the second oil may be 1,000 mPas or less, or 800 mPas or less, or 600 mPas or less, or 500 mPas or less, or 400 mPas or less.
- the viscosity of the second oil may be 1 mPas or greater, or 5 mPas or greater, or 10mPas or greater, or 30 mPas or greater, or 50 mPas or greater, or 80 mPas or greater.
- Suitable ranges include, for example, 1 - 2,000 mPas, or 1 - 1,000 mPas, or 10 - 800 mPas, or 30 - 500 mPas, or 80 - 400 mPas.
- the second oil in terms of its viscosity, it may be defined in terms of its molecular weight.
- the molecular weight may be 30,000 or less, optionally 20,000 or less, or 15,000 or less.
- the molecular weight may be 200 or greater, or 500 or greater, or 1,000 or greater, or 3,000 or greater, or 5,000 or greater. Suitable ranges include, for example, 200 - 30,000, or 1,000 - 20,000, or 5,000 - 30,000.
- the oils are miscible with each other and form a single phase, in contrast to oil combinations such as disclosed in for example Herbert et al, Graefe's Arch Clin Exp Opgthalmol 2004, 242, 250-254 wherein a silicone oil caps F 6 H 8 .
- Another point of distinction over Herbert et al. is that the present invention uses a first oil of higher molecular weight and higher viscosity.
- first oil and the second oil may be silicone oils.
- first oil and the second oil may be a polydimethylsiloxane.
- the amount of first oil by weight in the composition may be 25% by weight or more, or 30% by weight or more, or 40% by weight or more, e.g. 20%-45% or 25%-30% by weight.
- the composition can be used to replace part or all of the vitreous gel in the posterior part of the eye.
- the composition may be present within a syringe or syringe component (e.g. a barrel). This can make the medical procedure easier and safer and can ensure sterility and reduce the risk of contamination associated with preparing a composition and loading it into a syringe.
- the composition may thus be preloaded and premixed in a ready-to-use syringe.
- the process of preparation of the syringe may comprise: filling the mixture into a syringe; heat treatment; and packing and autoclaving the product.
- the heat treatment for the purpose of sterilizing the mixture and the inside of the syringe, may optionally take place at 120 to 180°C.
- the autoclaving for the purpose of sterilising the product on the outside, may optionally take place at 120 to 140°C.
- a yet further aspect of the present invention provides for a kit of parts for producing a composition as described above comprising oils as defined above.
- the kit of parts may further comprise a means by which to contact the oils together so as to form a mixture prior to use.
- the kit may therefore provide an apparatus such as a mixing vessel (or similar), so that the composition can be prepared prior to use.
- the kit may further comprise a means by which to measure a given amount of the oils prior to mixing and this will allow an individual to prepare a composition with bespoke properties prior to use.
- the blend was prepared as follows.
- the low viscosity silicone oil was added to a polystyrene container (ex Bibby Sterilin) followed by the high molecular weight additive.
- the mixture was stirred for 5 days on a platform mixer (model Rotamax 120 ex Heidolph) and then vigorously mixed using an overhead stirrer for 66 hours. Finally, the mixture was stirred using a roller mixer (SRT2 ex Stuart Scientific). All mixing was done at ambient temperature (20-25°C).
- the shear viscosity of the composition was measured at 25°C using a TA Instruments Advanced Rheometer AR1000. Injection speeds were measured through a 23 and 25 gauge surgical needle (both part of an Alcon Constellation Vision System Viscous Fluid Control Pack Ref: 8065750957) using an Accurus victrectomy machine. Injection tests were done at ambient temperature (20-25°C).
- Table 1 Composition Shear Viscosity (Pas) Injection Time (s) - 10 ml 10 s-1 25s-1 100s-1 23 Gauge 25 Gauge Run 1 Run 2 Silicone Oil 1000 mPas 1.091 1.093 1.096 18 18 35 34 Silicone Oil 5000 mPas 5.496 5.501 5.520 70 71 137 135 Silicone Oil 100 mPas plus 423,000 MW additive 13.44 12.62 9.318 24 24 48 44
- the addition of the high molecular weight additive has significantly reduced the injection time compared to the Silicone Oil 5000 control even though the shear viscosity of the test composition is much higher than that of the Silicone Oil 5000.
- the injection speed of the test composition also approaches that of the Silicone Oil 1000 mPas oil even though the shear viscosity of the test composition is much higher than 1000 mPas oil.
- the blend was prepared as follows.
- the low viscosity silicone oil was added to a polystyrene container (ex Bibby Sterilin) followed by the high molecular weight additive.
- the mixture was stirred for 2 hours on a platform mixer (model Rotamax 120 ex Heidolph) and then vigorously mixed using an overhead stirrer for 48 hours. Finally, the mixture was stirred using a roller mixer (SRT2 ex Stuart Scientific). All mixing was done at ambient temperature (20-25°C).
- the shear viscosity of the composition was measured at 25°C using a TA Instruments Advanced Rheometer AR1000. Injection speeds were measured through a 23 and 25 gauge surgical needle (both part of an Alcon Constellation Vision System Viscous Fluid Control Pack Ref: 8065750957) using an Accurus victrectomy machine. Injection tests were done at ambient temperature (20-25°C).
- Example 1 it is evident that the addition of the high molecular weight additive has significantly reduced the injection time compared to the Silicone Oil 5000 control even though the shear viscosity of the test composition is higher than that of the Silicone Oil 5000.
Abstract
The present invention relates to a composition comprising at least a first oil and a second oil, wherein the oils are miscible, wherein the first oil has a molecular weight of 100,000 or greater, and is present in an amount of at least 20% by weight, and wherein the second oil has a viscosity of 2,000 mPas or less.
Description
- The present invention relates to an oil composition and its use in the treatment of retinal detachment.
- Retinal detachment is the separation of the neurosensory retina from its underlying pigment epithelium. Untreated, retinal detachment can result in permanent vision loss or blindness. Retinal detachment is caused by traction of the vitreous upon the retina. The traction can be 'dynamic', caused by eye movements and thus relative movement of the vitreous and the retina; or 'static', due to contraction of membranes on the surface of the retina. Retinal detachments are associated with myopia, pseudophakia, trauma and diabetes; it is often the common pathway leading to blindness in a host of ophthalmic eye diseases.
- Where a retinal detachment is associated with retinal breaks (also referred to as perforations, holes or tears), fluid gains access from the vitreous cavity to the subretinal space. This form of retinal detachment is referred to as 'Rhegmatogenous'.
- One effective method of closing retinal breaks involves the application of explants outside the eye in order to buckle the sclera (such as described in
US 6,547,714 ). - Another method involves the use of internal tamponades. Internal tamponades are agents injected into the vitreous cavity to occlude retinal breaks. They are fluids that are immiscible with water and form an interface with it. The fluid can be gaseous such as air, sulphur hexafluoride (SF6) or perfluoropropane (C3F8). These gases can be used undiluted in small volumes or mixed with air and totally fill the vitreous cavity. The liquids include perfluorocarbon liquids, semifluorinated alkanes or alkenes and silicone oil. Of these, only silicone oil can be tolerated in the eye for more than a few weeks. Prolonged use of any of the other liquids will give rise to retinal toxicity as demonstrated by inflammatory reaction or by histological changes.
- Whilst these methods of treatment can be successful, they often require multiple treatments and there is always a danger of physical damage to the retina itself. Furthermore, there are also other dangers associated with these procedures such as the risk of infection, bleeding, high pressure inside the eye and the possibility of cataract development and these procedures often require a second operation to be undertaken.
- Retinal detachments can also be treated by means of pneumatic retinopexy, whereby a gas bubble is injected into the vitreous space so as to help push the retinal tear back against the wall of the eye. This method can also be used in conjunction with the laser and cryo-surgical techniques if required. The gases preferred for such operations are commonly either perfluoropropane (C3F8) or sulphur hexafluoride (SF6), which when mixed with sterile air have the properties of remaining in the eye for extended periods of time.
RU2235527 - Another method of treatment involves a vitrectomy whereby all or part of the vitreous gel is removed from the eye and replaced with a tamponade agent, such as a perfluorocarbon liquid, silicone oil or a gas (using a similar gaseous composition as described above) and the eye is allowed to fill with the body's own fluid over time. In this technique, a small incision is made in the wall of the eye and the vitreous gel is removed by means of a small cutting device. As the vitreous gel is removed, a saline solution is used to maintain the pressure by a continuous infusion. This solution is then exchanged with an air infusion following which an air and gas mixture is injected. Alternatively, perfluorocarbon liquids, semifluorinated alkanes or alkenes and more commonly silicone oil is injected as a tamponade agent. The tamponade agent is the immiscible fluid that occludes retinal breaks because of its interfacial tension and its buoyancy. The tamponade material is therefore intended to close the retinal tear and reoppose the retina on the underlying choroids.
- As taught in, for example,
WO 2006/122973 , it is important to avoid emulsification of the oil within the eye. Emulsification causes a number of specific problems; firstly the emulsified droplets can stimulate adverse biological responses including inflammatory reactions. Secondly, blocking of fluid to the eye decreases aqueous outflow and can cause raised intraocular pressure and glaucoma. Thirdly, reduction of vision by opacification of the fluid within the eye, and lastly the emulsion cannot tamponade the retina. - It is also desirable to be able to inject a composition into the eye, and to remove it from the eye, at a reasonable rate and under reasonable conditions. Whilst highly viscous oils can be injected under increasingly high pressures through small incisions into the eye, the same cannot be said of removal. The maximum suction force that can be generated by a suction pump is one atmosphere pressure, and this often results in a very low flow and thus a long time for the extraction of oil. This often requires a compromise involving the use of a larger bore instrument and cannula which in turn requires the use of larger incisions into the eye. Such large incisions are undesirable surgically. They weaken the eye and increase the chances of collateral damage such as vitreous incarceration or entry site related tears. Hypotony can also follow once the oil has been removed as the balanced salt solution can now flow out relatively unimpeded via an enlarged incision. In all instances it is preferable to have small incisions with the minimal amount of invasive surgery.
- It has generally been accepted that, if high molecular weight (or highly viscous) components are present in a composition, they should only be present in small amounts, to avoid slow injectability, the need for high pressure and/or the need for large incisions or large bores.
- For example,
WO 2006/122973 discloses compositions for use in the treatment of a detached retina, which contain only a small amount of a high molecular weight, viscous, additive, in a less viscous oil. - It is an object of the present invention to address one or more problems associated with the prior art procedures and in particular to provide a tamponade agent that can be effectively used in the treatment of retinal detachment. Furthermore, it is an object of the present invention to provide a tamponade agent that has good injectability whilst maintaining other desirable characteristics.
- From a first aspect, the present invention provides a composition comprising at least a first oil and a second oil, wherein the oils are miscible, wherein the first oil has a molecular weight of 100,000 or greater, and is present in an amount of at least 20% by weight, and wherein the second oil has a viscosity of 2,000 mPas or less.
- From a further aspect the present invention provides the above-mentioned composition for use in therapy.
- From a further aspect the present invention provides the above-mentioned composition for use in the treatment of a detached retina.
- From a further aspect the present invention provides a method of treatment of a detached retina in a patient in need thereof comprising the administration of an effective amount of the above-mentioned composition.
- The present invention is directed to a composition which has a relatively large amount (compared to the prior art) of high molecular weight component diluted by a low viscosity component. Surprisingly the composition is very effective and exhibits a low injection time despite the fact that 20% or more by weight of a high molecular weight additive is used. The skilled person would expect the shear viscosity of the composition to be high because of the presence of the significant proportion of high molecular weight additive, and therefore would not expect the composition to be convenient to use. Surprisingly, despite this, the composition is very effective and is injectable in a short period of time.
- Optionally the molecular weight of the first oil may be 200,000 or greater, or 300,000 or greater. Optionally the molecular weight of the first oil may be up to 1,000,000, or up to 600,000, or up to 500,000, or up to 450,000. Possible molecular weight ranges therefore include 100,000 - 1,000,000, 200,000 - 600,000, 200,000 - 500,000, and 300,000 - 450,000, for example.
- Optionally, rather than defining the first oil in terms of its molecular weight, it may be defined in terms of its viscosity. The viscosity may be 10,000 mPas or greater, optionally 50,000 mPas or greater, optionally 100,000 mPas or greater, optionally 300,000 mPas or greater, optionally 500,000 mPas or greater, optionally 800,000 mPas or greater, optionally 1,000,000 mPas or greater. Optionally, the viscosity may be up to 25,000,000 mPas, optionally up to 10,000,000 mPas, optionally up to 5,000,000 mPas, optionally up to 1,000,000 mPas. Suitable ranges include, for example, 10,000 mPas to 25,000,000 mPas, 50,000 mPas to 10,000,000 mPas, or 100,000 mPas to 1,000,000 mPas.
- Optionally the viscosity of the second oil may be 1,000 mPas or less, or 800 mPas or less, or 600 mPas or less, or 500 mPas or less, or 400 mPas or less. Optionally the viscosity of the second oil may be 1 mPas or greater, or 5 mPas or greater, or 10mPas or greater, or 30 mPas or greater, or 50 mPas or greater, or 80 mPas or greater. Suitable ranges include, for example, 1 - 2,000 mPas, or 1 - 1,000 mPas, or 10 - 800 mPas, or 30 - 500 mPas, or 80 - 400 mPas.
- Optionally, rather than defining the second oil in terms of its viscosity, it may be defined in terms of its molecular weight. The molecular weight may be 30,000 or less, optionally 20,000 or less, or 15,000 or less. Optionally the molecular weight may be 200 or greater, or 500 or greater, or 1,000 or greater, or 3,000 or greater, or 5,000 or greater. Suitable ranges include, for example, 200 - 30,000, or 1,000 - 20,000, or 5,000 - 30,000.
- The oils are miscible with each other and form a single phase, in contrast to oil combinations such as disclosed in for example Herbert et al, Graefe's Arch Clin Exp Opgthalmol 2004, 242, 250-254 wherein a silicone oil caps F6H8. Another point of distinction over Herbert et al. is that the present invention uses a first oil of higher molecular weight and higher viscosity.
- Optionally one or both of the first oil and the second oil may be silicone oils. Optionally one or both of the first oil and the second oil may be a polydimethylsiloxane.
- Optionally the amount of first oil by weight in the composition may be 25% by weight or more, or 30% by weight or more, or 40% by weight or more, e.g. 20%-45% or 25%-30% by weight.
- The composition can be used to replace part or all of the vitreous gel in the posterior part of the eye.
- In a further aspect of the present invention the composition may be present within a syringe or syringe component (e.g. a barrel). This can make the medical procedure easier and safer and can ensure sterility and reduce the risk of contamination associated with preparing a composition and loading it into a syringe. The composition may thus be preloaded and premixed in a ready-to-use syringe.
- The process of preparation of the syringe may comprise: filling the mixture into a syringe; heat treatment; and packing and autoclaving the product. The heat treatment, for the purpose of sterilizing the mixture and the inside of the syringe, may optionally take place at 120 to 180°C. The autoclaving, for the purpose of sterilising the product on the outside, may optionally take place at 120 to 140°C.
- A yet further aspect of the present invention provides for a kit of parts for producing a composition as described above comprising oils as defined above.
- The kit of parts may further comprise a means by which to contact the oils together so as to form a mixture prior to use. The kit may therefore provide an apparatus such as a mixing vessel (or similar), so that the composition can be prepared prior to use. The kit may further comprise a means by which to measure a given amount of the oils prior to mixing and this will allow an individual to prepare a composition with bespoke properties prior to use.
- The present invention will now be more particularly described in non-limiting detail with reference to the following examples:
- An experiment was conducted to examine the effect of adding a high molecular weight polydimethylsiloxane polymer (PS050 ex Fluorochem, England; molecular weight 423,000) to a low viscosity polydimethylsiloxane oil (Silicone Oil 100 mPas viscosity ex Dow Corning, USA). The amount of high molecular weight additive in the composition was 25.0% by weight.
- The blend was prepared as follows. The low viscosity silicone oil was added to a polystyrene container (ex Bibby Sterilin) followed by the high molecular weight additive. The mixture was stirred for 5 days on a platform mixer (model Rotamax 120 ex Heidolph) and then vigorously mixed using an overhead stirrer for 66 hours. Finally, the mixture was stirred using a roller mixer (SRT2 ex Stuart Scientific). All mixing was done at ambient temperature (20-25°C).
- The shear viscosity of the composition was measured at 25°C using a TA Instruments Advanced Rheometer AR1000. Injection speeds were measured through a 23 and 25 gauge surgical needle (both part of an Alcon Constellation Vision System Viscous Fluid Control Pack Ref: 8065750957) using an Accurus victrectomy machine. Injection tests were done at ambient temperature (20-25°C).
- Silicone Oil 5000 mPas viscosity and Silicone Oil 1000 mPas viscosity (both ex Alamedics GmbH, Germany) were used as controls.
- The results are shown below in Table 1.
Table 1. Composition Shear Viscosity (Pas) Injection Time (s) - 10 ml 10 s-1 25s-1 100s-1 23 Gauge 25 Gauge Run 1 Run 2 Silicone Oil 1000 mPas 1.091 1.093 1.096 18 18 35 34 Silicone Oil 5000 mPas 5.496 5.501 5.520 70 71 137 135 Silicone Oil 100 mPas plus 423,000 MW additive 13.44 12.62 9.318 24 24 48 44 - It is evident that the addition of the high molecular weight additive has significantly reduced the injection time compared to the Silicone Oil 5000 control even though the shear viscosity of the test composition is much higher than that of the Silicone Oil 5000. The injection speed of the test composition also approaches that of the Silicone Oil 1000 mPas oil even though the shear viscosity of the test composition is much higher than 1000 mPas oil.
- An experiment was conducted to examine the effect of adding a high molecular weight polydimethylsiloxane polymer (PS049 ex Fluorochem, England; molecular weight 260,000) to a low viscosity polydimethylsiloxane oil (Silicone Oil 350 mPas viscosity ex ABLR GmbH&Co., Germany). The amount of high molecular weight additive in the composition was 25.0% by weight.
- The blend was prepared as follows. The low viscosity silicone oil was added to a polystyrene container (ex Bibby Sterilin) followed by the high molecular weight additive. The mixture was stirred for 2 hours on a platform mixer (model Rotamax 120 ex Heidolph) and then vigorously mixed using an overhead stirrer for 48 hours. Finally, the mixture was stirred using a roller mixer (SRT2 ex Stuart Scientific). All mixing was done at ambient temperature (20-25°C).
- The shear viscosity of the composition was measured at 25°C using a TA Instruments Advanced Rheometer AR1000. Injection speeds were measured through a 23 and 25 gauge surgical needle (both part of an Alcon Constellation Vision System Viscous Fluid Control Pack Ref: 8065750957) using an Accurus victrectomy machine. Injection tests were done at ambient temperature (20-25°C).
- Silicone Oil 5000 mPas viscosity and Silicone Oil 1000 mPas viscosity (both ex Alamedics GmbH, Germany) were used as controls.
- The results are shown below in Table 2.
Table 2. Composition Shear Viscosity (Pas) Injection Time (s) - 10 ml 10 s-1 25s-1 100s-1 23 Gauge 25 Gauge Run 1 Run 2 Silicone Oil 1000 mPas 1.091 1.093 1.096 18 18 35 34 Silicone Oil 5000 mPas 5.496 5.501 5.520 70 71 137 135 Silicone Oil 350 mPas plus 260,000 MW additive 7.945 7.850 7.125 29 31 59 61 - As in Example 1, it is evident that the addition of the high molecular weight additive has significantly reduced the injection time compared to the Silicone Oil 5000 control even though the shear viscosity of the test composition is higher than that of the Silicone Oil 5000.
- These experiments show that use of a large amount (over 20%) of a high molecular weight oil in combination with a low viscosity oil results in surprisingly effective injectability which is of considerable importance in the treatment of a detached retina.
Claims (14)
- A composition comprising at least a first oil and a second oil, wherein the oils are miscible, wherein the first oil has a molecular weight of 100,000 or greater, and is present in an amount of at least 20% by weight, and wherein the second oil has a viscosity of 2,000 mPas or less.
- A composition as claimed in claim 1 wherein the second oil has a viscosity of 1,000 mPas or less.
- A composition comprising at least a first oil and a second oil, wherein the oils are miscible, wherein the first oil has a viscosity of 10,000 mPas or greater, and is present in an amount of at least 20% by weight, and wherein the second oil has a viscosity of 2,000 mPas or less.
- A composition as claimed in claim 3 wherein the second oil has a viscosity of 1,000 mPas or less.
- A composition comprising at least a first oil and a second oil, wherein the oils are miscible, wherein the first oil has a molecular weight of 100,000 or greater, and is present in an amount of at least 20% by weight, and wherein the second oil has a molecular weight of 30,000 or less.
- A composition comprising at least a first oil and a second oil, wherein the oils are miscible, wherein the first oil has a viscosity of 10,000 mPas or greater, and is present in an amount of at least 20% by weight, and wherein the second oil has a molecular weight of 30,000 or less.
- A composition as claimed in any preceding claim wherein the first oil and the second oil are silicone oils.
- A composition as claimed in claim 5 wherein the first oil and the second oil are polydimethylsiloxanes.
- A composition as claimed in any preceding claim for use as a medicament.
- A composition as claimed in any preceding claim for use in the treatment of a detached retina.
- A syringe or syringe component comprising a composition as claimed in any preceding claim.
- Method of treatment of a detached retina comprising the use of a composition or syringe as claimed in any preceding claim.
- A kit of parts comprising a first oil and a second oil as defined in any of claims 1 to 8.
- A method of preparing a composition as claimed in any of claims 1 to 8 comprising mixing a first oil and a second oil as defined in any of claims 1 to 8, thereby forming a single phase mixture.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201502565A GB201502565D0 (en) | 2015-02-16 | 2015-02-16 | Composition and use in treatment of a detached retina |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3146959A1 true EP3146959A1 (en) | 2017-03-29 |
Family
ID=52781673
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16152302.2A Withdrawn EP3146959A1 (en) | 2015-02-16 | 2016-01-21 | Composition and use in treatment of a detached retina |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP3146959A1 (en) |
GB (1) | GB201502565D0 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1452165A2 (en) * | 2003-02-25 | 2004-09-01 | L'oreal | Bilayered make-up product, its uses and make-up kit containing this product |
WO2006122973A1 (en) * | 2005-05-19 | 2006-11-23 | The University Of Liverpool | Composition for treatment of a detached retina and method of production thereof |
US20130345149A1 (en) * | 2011-03-03 | 2013-12-26 | Allergan, Inc. | Silicone-based ophthalmic formulations |
EP2730291A1 (en) * | 2012-11-09 | 2014-05-14 | Fluoron Gmbh | Internal Tamponade Composition |
-
2015
- 2015-02-16 GB GB201502565A patent/GB201502565D0/en not_active Ceased
-
2016
- 2016-01-21 EP EP16152302.2A patent/EP3146959A1/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1452165A2 (en) * | 2003-02-25 | 2004-09-01 | L'oreal | Bilayered make-up product, its uses and make-up kit containing this product |
WO2006122973A1 (en) * | 2005-05-19 | 2006-11-23 | The University Of Liverpool | Composition for treatment of a detached retina and method of production thereof |
US20130345149A1 (en) * | 2011-03-03 | 2013-12-26 | Allergan, Inc. | Silicone-based ophthalmic formulations |
EP2730291A1 (en) * | 2012-11-09 | 2014-05-14 | Fluoron Gmbh | Internal Tamponade Composition |
Also Published As
Publication number | Publication date |
---|---|
GB201502565D0 (en) | 2015-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1881818B1 (en) | Composition for treatment of a detached retina and method of production thereof | |
Barca et al. | Silicone oil: different physical proprieties and clinical applications | |
Chen et al. | Silicone oil in vitreoretinal surgery: indications, complications, new developments and alternative long‐term tamponade agents | |
Morescalchi et al. | Heavy silicone oil and intraocular inflammation | |
Chang et al. | Perfluoropropane gas in the management of proliferative vitreoretinopathy | |
Giordano et al. | Silicone oils as vitreous substitutes | |
Rizzo et al. | Vitreous substitute and tamponade substances for microincision vitreoretinal surgery | |
Han et al. | Management of complex retinal detachment with combined relaxing retinotomy and intravitreal perfluoro-n-octane injection | |
Chan et al. | Factors influencing the shear rate acting on silicone oil to cause silicone oil emulsification | |
US20040167480A1 (en) | Administration of multiple viscoelastic solutions with a multi-compartment syringe | |
CN108339147B (en) | Adhesive for vitreous or retinal surgical incision and adhesive system | |
Kertes et al. | Use of silicone oil in vitreous surgery | |
EP3146959A1 (en) | Composition and use in treatment of a detached retina | |
Hammer et al. | Tolerance of perfluorocarbons, fluorosilicone, and silicone liquids in the vitreous | |
EP2730291A1 (en) | Internal Tamponade Composition | |
Shahid et al. | Sub-Tenon versus peribulbar anesthesia in phacoemulsification a comparative study | |
Tornambe | Pneumatic retinopexy | |
Unosson et al. | Liquid silicone in the treatment of retinal detachment | |
Hoerauf et al. | Severe emulsification after combined use of a partially fluorinated alkane and silicone oil | |
Jain et al. | Tamponading Agents in Vitreoretinal Surgery | |
Ghoneim | Modified capsulorhexis for fiuid-filled mature cataracts | |
Buratto et al. | Cataract surgery complications | |
Yavuzer et al. | The Effect of the Use of Vent Cannula on Intraocular Pressure in the Early Postoperative Period in Silicone Oil Tamponade Application Due to Rhegmatogenous Retinal Detachment | |
Gopal et al. | 41 Silicone Oil and Intraocular Gases in the Management of Retinal Detachment | |
Joussen et al. | Vitrectomy in retinal vascular disease: Surgical principles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170930 |